



## Press release

### New data presented at MDS Congress of ABBV-0805 in Parkinson's disease

**Stockholm, September 10, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti- $\alpha$ -synuclein antibody ABBV-0805 at the International Congress of Parkinson's disease and movement disorders® (MDS), held virtually September 17 to 22, 2021. The presentation, which has been selected as a *Top Abstract*, includes data showing ABBV-0805's ability to selectively target soluble toxic  $\alpha$ -synuclein aggregates.**

BioArctic will present one abstract at the congress, focusing on the preclinical findings that continue to support ABBV-0805 for development in Parkinson's disease. The abstract has been selected as a "Top Abstract" presentation and BioArctic's Vice President Head of Research, Johanna Fälting, has been invited to participate in a live faculty discussion as part of the conference session called *Recent and Ongoing Industry-led Clinical Trial Top Abstracts*. The data to be presented shows that ABBV-0805 selectively targets soluble toxic  $\alpha$ -synuclein aggregates such as oligomers and protofibrils. In addition, ABBV-0805 displays a dose-dependent reduction of both soluble and insoluble  $\alpha$ -synuclein aggregates in mice brains, preventing  $\alpha$ -synuclein to spread, delaying motor-symptoms and prolonging the lifespan. Furthermore, binding of ABBV-0805 to pathological  $\alpha$ -synuclein in postmortem brains of Parkinson's disease patients has also been observed.

"It's very encouraging to see the data on ABBV-0805 presented at the MDS congress and we look forward to the continued development of this antibody as a potential disease-modifying treatment for patients with Parkinson's disease," said BioArctic's CEO Gunilla Osswald.

All abstracts from the MDS congress are available on the congress' website.

---

*This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.*

**For further information, please contact:**

Gunilla Osswald, CEO

E-mail: [gunilla.osswald@bioarctic.se](mailto:gunilla.osswald@bioarctic.se)

Phone: +46 8 695 69 30

Oskar Bosson, VP Communications and Investor Relations

E-mail: [oskar.bosson@bioarctic.se](mailto:oskar.bosson@bioarctic.se)

Phone: +46 70 410 71 80



*The information was released for public disclosure, through the agency of the contact persons above, on September 10, 2021, at 16.40 a.m. CET.*

**Note to editors**

**About ABBV-0805**

ABBV-0805 is a monoclonal antibody drug candidate that is designed to selectively bind and eliminate aggregated forms of alpha-synuclein such as oligomers and protofibrils, which participates in neurodegenerative maladies including Parkinson's disease. The goal is to develop a disease modifying treatment that stops or slows down the progression of Parkinson's disease.

**About the BioArctic AbbVie collaboration**

BioArctic and AbbVie have been collaborating since 2016 when the parties entered into a research agreement. AbbVie was granted the option to license the right to develop and commercialize BioArctic's portfolio of antibodies against alpha-synuclein for Parkinson's disease and other potential indications. At the end of 2018, AbbVie exercised this option. In February 2019, the U.S. Food and Drug Administration, FDA, approved the application to conduct a clinical study with ABBV-0805 and the Phase 1 study started in March 2019. AbbVie is responsible for the clinical development of ABBV-0805. The scope of ABBV-0805 may be expanded to include, for example, Lewy body dementia and multiple system atrophy.

**About BioArctic AB**

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit [www.bioarctic.com](http://www.bioarctic.com).